AMPHASTAR PHARMACEUTICALS IN (AMPH)

US03209R1032 - Common Stock

44.55  +0.46 (+1.04%)

After market: 44.55 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (11/21/2024, 8:12:10 PM)

After market: 44.55 0 (0%)

44.55

+0.46 (+1.04%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month2.98%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.15B
Shares
PE11.66
Fwd PE10
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AMPH Daily chart

Company Profile

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 1,761 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Company Info

AMPHASTAR PHARMACEUTICALS IN

11570 6th St

Rancho Cucamonga CALIFORNIA 91730

P: 19099809484

CEO: Jack Y. Zhang

Employees: 1761

Website: https://amphastar.com/

AMPH News

News Image9 days ago - ACCESSWIREAmphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
News Image16 days ago - ACCESSWIREAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
News Imagea month ago - Investor's Business DailyAmphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade

Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.

News Image2 months ago - Market News VideoBullish Two Hundred Day Moving Average Cross - AMPH
News Image3 months ago - ACCESSWIREAmphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
News Image4 months ago - InvestorPlaceAMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

AMPH Twits

Here you can normally see the latest stock twits on AMPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example